GLP-1 Medications This is one of the most common questions families ask
Keep Emergency Protein Available Store these in your: Vehicle Work desk Gym bag Purse Examples: Protein shakes Protein bars Beef jerky Tuna packets 3
Transdermal delivery systems could potentially offer advantages over subcutaneous injections, including improved patient acceptability and reduced injection-site reactions
Retatrutide Research Findings Phase II clinical trial data published in the New England Journal of Medicine (Jastreboff et al., June 2023) reported the following findings in adult participants with obesity over 48 weeks: Up to 24.2% mean body weight reduction at the highest dose (12mg weekly) Significant reductions in visceral adipose tissue Improved fasting glucose and insulin sensitivity markers Reductions in waist circumference averaging 1822cm Greater efficacy than both Semaglutide 2.4mg and Tirzepatide 15mg in indirect comparisons These findings represent some of the most significant weight reduction outcomes ever observed in a clinical trial for a non-surgical intervention, and have driven substantial research interest in the UK and globally
One built for your body
While advancements in GLP-1 pharmacokinetics, such as extending the half-life from weekly to quarterly subcutaneous injections and new technologies in controlled drug delivery (e.g., erodible coatings to construct time-controlled release systems) are promising, the development of less invasive delivery methods remains imperative [11, 2123]
